Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children 3 Months to Less Than 36 Months of Age

Trial Profile

Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children 3 Months to Less Than 36 Months of Age

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Efavirenz (Primary) ; Antituberculars; Nucleoside reverse transcriptase inhibitors; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 May 2016 Status changed from active, no longer recruiting to completed.
    • 25 Feb 2016 Interim results (n=8) presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 07 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top